2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) CFO Victoria Eatwell sold 2,592 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $12,830.40. Following the completion of the sale, the chief financial officer now owns 444,387 shares of the company's stock, valued at $2,199,715.65. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
2seventy bio Stock Performance
TSVT remained flat at $4.95 during trading hours on Friday. The company had a trading volume of 665,244 shares, compared to its average volume of 605,066. The stock has a market cap of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a 12-month low of $2.29 and a 12-month high of $5.99. The business has a fifty day moving average of $2.99 and a 200-day moving average of $3.70.
Institutional Investors Weigh In On 2seventy bio
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new position in shares of 2seventy bio during the 3rd quarter worth $25,000. China Universal Asset Management Co. Ltd. purchased a new position in 2seventy bio during the fourth quarter worth about $32,000. BNP Paribas Financial Markets purchased a new position in 2seventy bio during the fourth quarter worth about $35,000. ProShare Advisors LLC acquired a new stake in shares of 2seventy bio during the fourth quarter valued at about $48,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of 2seventy bio in the 4th quarter valued at approximately $52,000. Hedge funds and other institutional investors own 93.90% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 2seventy bio in a research note on Friday, March 7th. Leerink Partners reaffirmed a "market perform" rating and issued a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Morgan Stanley reduced their price objective on 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Friday, March 14th. Finally, Leerink Partnrs cut 2seventy bio from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $6.67.
Get Our Latest Analysis on 2seventy bio
About 2seventy bio
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Further Reading
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
